Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies.

Diana S OsorioIra J DunkelKelly Ann CervoneRakesh Kumar GoyalK M Steve LoJonathan L FinlaySharon L Gardner

Published in: Pediatric blood & cancer (2017)

Two cycles of high-dose thiotepa with AHCR were well tolerated even in these heavily pretreated patients. This therapy may provide prolonged survival in patients with recurrent malignant brain tumors, particularly medulloblastoma and CNS GCT.

Keyphrases

poor prognosis
high dose
long non coding rna
end stage renal disease
cell therapy
bone marrow
ejection fraction
chronic kidney disease
low dose
single cell
peritoneal dialysis
patient reported outcomes